Gene Therapy for Ovarian Cancer - A Pipeline Analysis Report

Gene therapy for ovarian cancer industry insights

Technavio’s market research analysts have predicted that with the emergence of gene therapy as an approach for the treatment of ovarian cancer, the global ovarian cancer market will witness considerable growth in the coming years. With the potential to cure ovarian cancer by replacing faulty genes with normal ones, replacement gene therapy will gain prominence during the next few years.

 Get A Free Sample

According to gene therapy for ovarian cancer industry analysis, companies are focusing on evaluating pipeline molecules for recurrent ovarian epithelial cancer and platinum-resistant ovarian cancer. Our market research analysts have also identified that most of the gene therapy candidates in the pipeline are being developed for platinum-resistant ovarian cancer.

Gene therapy industry report: Companies covered

This pipeline analysis report provides a comprehensive analysis of the companies that are involved in the development of gene therapy molecules for the treatment of ovarian cancer. The report provides detailed information on the various stages of molecules developed by companies for different indications. Furthermore, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Takara Bio
• VBL Therapeutics
• CELSION
• Targovax

Therapeutic assessment of the gene therapy for ovarian cancer by route of administration

• Intravenous
• Intratumoral
• Intraperitoneal

The walls of abdominal organs such as the stomach and intestines and the abdominal (peritoneal) cavity are lined with a thin and transparent membrane called peritoneum. According to our research experts, the majority of gene therapy molecules currently in the pipeline for ovarian cancer are developed for the intraperitoneal route of administration, in which, the drug is administered directly into the peritoneum.

Therapeutic assessment of the gene therapy for ovarian cancer by target

• NY-ESO-1
• p53 gene
• IL – 12
• Thymidine Kinase

According to this pipeline analysis report, the current pipeline molecules for ovarian cancer gene therapy are mainly evaluated by NY-ESO-1 target therapeutic assessment. However, several companies have not disclosed the target for most of the molecules in the early development stages.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages of ovarian cancer?
• What are the companies that are currently involved in the development of gene therapy molecules for ovarian cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule.

Technavio also offers customization on reports based on specific client requirement.